Cereno Scientific extends preclinical development agreement with University of Michigan to transition CS014 into clinical phase

Cereno Scientific today announced that the collaboration agreement for CS014 with the University of Michigan will be extended to include a full preclinical development program. The objective of the signed development agreement is to successfully bring CS014 into a clinical Phase I program. The IND-enabling work will be conducted at the University of Michigan, a top-ranked public research university in the US with an extensive track record of successful collaborations with industry. CS014 is in development within cardiovascular diseases.

“We started working with Dr. Michael Holinstat and his research team at University of Michigan about a year ago. The promising results delivered with CS014 in initial animal studies made the decision easy to extend the collaboration to a full preclinical program,” says Sten R. Sörensen, CEO at Cereno Scientific.

The preclinical program CS014 was acquired from Emeriti Bio in March 2019 and has since been developed together by Cereno and Emeriti Bio. A collaboration with the University of Michigan under Dr. Michael Holinstat started in March 2020 comprising studies with the purpose of evaluating which compound in the program had the highest potential of success, using both in vitro and in vivo model systems.

“I’m pleased to continue to work with CS014 and Cereno. The results from the initial studies show promising potential of this program and we look forward to fully delineating the role of CS014 for intervention in a preclinical program,” says Dr Michael Holinstat PhD, FAHA, Department of Pharmacology, Internal Medicine (Division of Cardiovascular Medicine), and Vascular Surgery at University of Michigan Medical School.

The University of Michigan is a top-ranked public research university with one of the largest annual collegiate research budgets of any university in the US. Over $1.6 billion is spent on research and development annually across its 2.8 million square feet of laboratory space. The university has 6,200 faculty members and roughly 38,000 employees.

Cereno now has two ongoing preclinical development programs running in parallel, CS585 and CS014, with the aim to successfully transition to clinical Phase I, first-in-man, studies. As the development programs proceed over the upcoming 24 months, Cereno will share more details about both preclinical programs.

 

For further information, please contact:
Daniel Brodén, CFO
Tel: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in September 2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.

Subscribe

Documents & Links

Quotes

We started working with Dr. Michael Holinstat and his research team at University of Michigan about a year ago. The promising results delivered with CS014 in initial animal studies made the decision easy to extend the collaboration to a full preclinical program.
Sten R. Sörensen, CEO at Cereno Scientific
I’m pleased to continue to work with CS014 and Cereno. The results from the initial studies show promising potential of this program and we look forward to fully delineating the role of CS014 for intervention in a preclinical program.
Dr. Michael Holinstat PhD, FAHA, Department of Pharmacology, Internal Medicine (Division of Cardiovascular Medicine), and Vascular Surgery at University of Michigan Medical School